ImmuPharma PLC - London-based drug discovery and development company - Will start phases two and three of the clinical trial for Lupuzor in the seocnd half of 2023, following talks with the US Food & Drug Administration. Says the clinical trial will be supported by Avion Pharmaceuticals. Adds further details of the trial will be shared at a later stage. Lupuzor, or P140, is a potential treatment for Lupus disease.
Chief Executive Officer Tim McCarthy says: ‘Avion and ourselves are confident in the new design of the Phase 2/3 adaptive clinical trial and in ultimately delivering a new efficacious and safe therapy for Lupus patients.’
Current stock price: 3.30 pence, down 1.4%
12-month change: down 44%
Copyright 2023 Alliance News Ltd. All Rights Reserved.
